glp-1 drug for weight loss Another Weight-Loss Trial Win Weekly New GLP-1 Pill Foundayo (Orforglipron)
Description
Commercial availability would likely follow in early 2027, pending approval and standard launch timelines
The body mass index (BMI) of individuals with IBD has seen an upward shift with 15%-40% of adult patients reported to be obese and 20%-40% overweight
Conclusion The GLP-1 RAs in people with obesity or type 2 diabetes are associated with a significant reduction in all-cause death, alongside an increased risk of pancreatic adverse eventsparticularly acute pancreatitismost pronounced during the first 6 months of treatment
Finan are employees of Novo Nordisk
2.1% vs
